Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 165 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors March 27, 2025 Time to take on 9 new Cancer Grand Challenges March 8, 2023 EMA Recommends Extension of Therapeutic Indications for Darolutamide August 7, 2025 New Technology System Allows Patients To Get A Mammogram And Biopsy... June 30, 2020 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade...
